Published in Infect Immun on October 01, 1990
Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect Immun (2003) 1.26
Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infect Immun (2007) 1.15
Monoclonal antibodies and toxins--a perspective on function and isotype. Toxins (Basel) (2012) 1.09
Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein. Infect Immun (2004) 1.09
Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infect Immun (1991) 1.09
Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway. Infect Immun (1999) 1.04
Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice. Infect Immun (2008) 1.03
Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein. Infect Immun (1994) 1.02
Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin. J Exp Med (1993) 1.01
Evading the proteasome: absence of lysine residues contributes to pertussis toxin activity by evasion of proteasome degradation. Infect Immun (2007) 1.00
Bordetella pertussis infection exacerbates influenza virus infection through pertussis toxin-mediated suppression of innate immunity. PLoS One (2011) 0.92
Proteolytic cleavage of pertussis toxin S1 subunit is not essential for its activity in mammalian cells. BMC Microbiol (2005) 0.91
Construction of minitransposons for constitutive and inducible expression of pertussis toxin in bvg-negative Bordetella bronchiseptica. Infect Immun (1991) 0.90
Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin. Infect Immun (1991) 0.89
Production of recombinant Bordetella pertussis serotype 2 fimbriae in Bordetella parapertussis and Bordetella bronchiseptica: utility of Escherichia coli gene expression signals. Infect Immun (1991) 0.88
Characterization of murine monoclonal antibodies that recognize defined epitopes of pertussis toxin and neutralize its toxic effect on Chinese hamster ovary cells. Infect Immun (1991) 0.87
Reversal of the CD4(+)/CD8(+) T-cell ratio in lymph node cells upon in vitro mitogenic stimulation by highly purified, water-soluble S3-S4 dimer of pertussis toxin. Infect Immun (2001) 0.86
Stable expression of pertussis toxin in Bordetella bronchiseptica under the control of a tightly regulated promoter. Appl Environ Microbiol (1997) 0.81
Enhancement of Bordetella parapertussis infection by Bordetella pertussis in mixed infection of the respiratory tract. FEMS Immunol Med Microbiol (2011) 0.79
Measurement of protein using bicinchoninic acid. Anal Biochem (1985) 74.03
A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem (1977) 36.95
Pertussis immunisation and serious acute neurological illness in children. Br Med J (Clin Res Ed) (1981) 8.48
Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics (1981) 7.58
Virulence factors of Bordetella pertussis. Annu Rev Microbiol (1986) 6.41
Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc Natl Acad Sci U S A (1982) 5.68
Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Infect Immun (1983) 5.03
Genetic analysis of phase change in Bordetella pertussis. Infect Immun (1984) 5.03
Improved techniques for the preparation of bacterial lipopolysaccharides. Can J Microbiol (1976) 4.62
The construction of a cloning vector designed for gene replacement in Bordetella pertussis. Gene (1986) 4.01
Development of a pertussis component vaccine in Japan. Lancet (1984) 3.94
Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells. J Infect Dis (1985) 3.66
Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis. J Infect Dis (1984) 3.48
Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J Biol Chem (1983) 3.31
Biological activities of crystalline pertussigen from Bordetella pertussis. Infect Immun (1981) 3.16
Identification of the predominant substrate for ADP-ribosylation by islet activating protein. J Biol Chem (1983) 3.11
Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis. Infect Immun (1981) 2.94
Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Infect Immun (1990) 2.89
Separation and purification of the hemagglutinins from Bordetella pertussis. Infect Immun (1983) 2.85
Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect Immun (1981) 2.77
Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun (1984) 2.72
A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. J Biol Chem (1983) 2.65
Lethal infection by Bordetella pertussis mutants in the infant mouse model. Infect Immun (1989) 2.45
The concept of pertussis as a toxin-mediated disease. Pediatr Infect Dis (1984) 2.45
Membrane receptors for bacterial toxins. Microbiol Rev (1983) 2.41
Aerosol infection of mice with Bordetella pertussis. Infect Immun (1980) 2.31
Reflections on the efficacy of pertussis vaccines. Rev Infect Dis (1988) 2.01
Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J Infect Dis (1984) 1.96
Macrophage behaviour during the complaisant phase of murine pertussis. Immunology (1969) 1.85
Protection against intranasal infection of mice with Bordetella pertussis. Dev Biol Stand (1985) 1.84
The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr (1984) 1.81
Molecular mechanisms of lymphocyte extravasation. I. Studies of two selective inhibitors of lymphocyte recirculation. J Immunol (1984) 1.80
The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J Biol Stand (1985) 1.79
Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med (1990) 1.67
Pertussis vaccine: present status and future prospects. Vaccine (1985) 1.63
Dual mechanisms involved in development of diverse biological activities of islet-activating protein, pertussis toxin, as revealed by chemical modification of lysine residues in the toxin molecule. Biochim Biophys Acta (1984) 1.62
Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity. Proc Natl Acad Sci U S A (1988) 1.61
ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis. Science (1988) 1.57
Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. Science (1988) 1.56
Synergistic effect of Bordetella pertussis lymphocytosis-promoting factor on protective activities of isolated Bordetella antigens in mice. Infect Immun (1983) 1.50
The interleukins. FASEB J (1989) 1.46
Pertussis toxin effects on T lymphocytes are mediated through CD3 and not by pertussis toxin catalyzed modification of a G protein. J Immunol (1989) 1.45
Identification of a region in the S1 subunit of pertussis toxin that is required for enzymatic activity and that contributes to the formation of a neutralizing antigenic determinant. Proc Natl Acad Sci U S A (1988) 1.40
Filamentous hemagglutinin and pertussis toxin promote adherence of Bordetella pertussis to cilia. Dev Biol Stand (1985) 1.39
Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines. J Immunol (1988) 1.26
Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2. J Immunol (1988) 1.14
In vitro inhibition of murine macrophage migration by Bordetella pertussis lymphocytosis-promoting factor. Infect Immun (1984) 1.12
Structure-function relationship of islet-activating protein, pertussis toxin: biological activities of hybrid toxins reconstituted from native and methylated subunits. Biochemistry (1986) 1.11
Lymphocytosis-promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation. Infect Immun (1984) 1.07
Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. Pediatr Infect Dis J (1988) 1.07
Identification of amino acid residues essential for the enzymatic activities of pertussis toxin. Proc Natl Acad Sci U S A (1989) 1.05
Inhibition of pertussis toxin binding to model receptors by antipeptide antibodies directed at an antigenic domain of the S2 subunit. Infect Immun (1989) 1.04
Whooping cough in adults. Br Med J (Clin Res Ed) (1981) 1.02
The efficacy of acellular pertussis vaccine. JAMA (1989) 0.97
Role of pertussigen (pertussis toxin) on the mouse protective activity of vaccines made from Bordetella species. Microbiol Immunol (1989) 0.95
Proliferative response of immune mouse T-lymphocytes to the lymphocytosis-promoting factor of Bordetella pertussis. Infect Immun (1984) 0.95
The effects of pertussis toxin and cholera toxin on mitogen-induced interleukin-2 production: evidence for G protein involvement in signal transduction. Cell Immunol (1988) 0.94
Signal transduction pathway for IL-1. Involvement of a pertussis toxin-sensitive GTP-binding protein in the activation of adenylate cyclase. J Immunol (1989) 0.94
Acellular pertussis vaccines: evaluation of reversion in a nude mouse model. J Biol Stand (1988) 0.83
The activity of purified Bordetella pertussis components in murine encephalopathy. J Biol Stand (1987) 0.82
Evaluation of the mouse model for study of encephalopathy in pertussis vaccine recipients. Infect Immun (1989) 0.82
Pertussis and pertussis vaccine. Can Med Assoc J (1985) 0.77
Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Infect Immun (1983) 5.03
Characterization of virulence plasmids and plasmid-associated outer membrane proteins in Shigella flexneri, Shigella sonnei, and Escherichia coli. Infect Immun (1983) 4.82
Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Infect Immun (1990) 2.89
Separation and purification of the hemagglutinins from Bordetella pertussis. Infect Immun (1983) 2.85
Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect Immun (1981) 2.77
Role of flagella in adherence, internalization, and translocation of Campylobacter jejuni in nonpolarized and polarized epithelial cell cultures. Infect Immun (1993) 2.63
Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis. Infect Immun (1988) 2.55
Aerosol infection of mice with Bordetella pertussis. Infect Immun (1980) 2.31
Filamentous hemagglutinin has a major role in mediating adherence of Bordetella pertussis to human WiDr cells. Infect Immun (1986) 2.18
Identification and molecular cloning of a gene encoding a fibronectin-binding protein (CadF) from Campylobacter jejuni. Mol Microbiol (1997) 2.17
Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J Infect Dis (1984) 1.96
Comparison of type 2 and type 6 fimbriae of Bordetella pertussis by using agglutinating monoclonal antibodies. Infect Immun (1988) 1.92
Species specificity of in vitro Escherichia coli adherence to host intestinal cell membranes and its correlation with in vivo colonization and infectivity. Infect Immun (1980) 1.89
Intracellular localization of the dermonecrotic toxin of Bordetella pertussis. Infect Immun (1979) 1.83
Genetic transfer of a mucosal adherence factor (R1) from an enteropathogenic Escherichia coli strain into a Shigella flexneri strain and the phenotypic suppression of this adherence factor. J Infect Dis (1983) 1.78
Nucleotide sequence and analysis of the gene in Borrelia burgdorferi encoding the immunogenic P39 antigen. FEMS Microbiol Lett (1994) 1.77
Energetics of glycylglycine transport in Escherichia coli. J Bacteriol (1974) 1.76
Agglutinating monoclonal antibodies that specifically recognize lipooligosaccharide A of Bordetella pertussis. Infect Immun (1988) 1.71
Evidence for proteolytic cleavage of the 120-kilodalton outer membrane protein of rickettsiae: identification of an avirulent mutant deficient in processing. Infect Immun (1992) 1.70
Homology between Borrelia burgdorferi OspC and members of the family of Borrelia hermsii variable major proteins. Gene (1994) 1.61
ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis. Science (1988) 1.57
Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. Science (1988) 1.56
Cloning and characterization of elastase genes from Pseudomonas aeruginosa. J Bacteriol (1987) 1.49
Activities of complete and truncated forms of pertussis toxin subunits S1 and S2 synthesized by Escherichia coli. Infect Immun (1987) 1.49
Evaluation of mixtures of purified Haemophilus influenzae outer membrane proteins in protection against challenge with nontypeable H. influenzae in the chinchilla otitis media model. Infect Immun (1993) 1.47
Purification and characterization of fimbriae isolated from Bordetella pertussis. Infect Immun (1985) 1.47
Altered synthetic response of Campylobacter jejuni to cocultivation with human epithelial cells is associated with enhanced internalization. Infect Immun (1992) 1.45
Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function. Hybridoma (1989) 1.43
Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin. Infect Immun (1991) 1.42
Alteration by cereolysin of the structure of cholesterol-containing membranes. Biochim Biophys Acta (1978) 1.40
Characteristics of the internalization and intracellular survival of Campylobacter jejuni in human epithelial cell cultures. Microb Pathog (1992) 1.39
Translocation of Campylobacter jejuni across human polarized epithelial cell monolayer cultures. J Infect Dis (1992) 1.37
The 120 kilodalton outer membrane protein (rOmp B) of Rickettsia rickettsii is encoded by an unusually long open reading frame: evidence for protein processing from a large precursor. Mol Microbiol (1991) 1.34
Species-specific binding of purified pili (AF/R1) from the Escherichia coli RDEC-1 to rabbit intestinal mucosa. Gastroenterology (1983) 1.30
Purification of cereolysin and the electrophoretic separation of the active (reduced) and inactive (oxidized) forms of the purified toxin. Infect Immun (1976) 1.17
Identification and characterization of an intervening sequence within the 23S ribosomal RNA genes of Campylobacter jejuni. Mol Microbiol (1994) 1.14
Factors that influence the interaction of Campylobacter jejuni with cultured mammalian cells. J Med Microbiol (1992) 1.13
Role of cholesterol in the action of cereolysin on membranes. Arch Biochem Biophys (1978) 1.11
A bactericidal monoclonal antibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis. Infect Immun (1992) 1.10
Purification and characterization of serotype 6 fimbriae from Bordetella pertussis and comparison of their properties with serotype 2 fimbriae. Infect Immun (1987) 1.10
The Genome Sequence DataBase version 1.0 (GSDB): from low pass sequences to complete genomes. Nucleic Acids Res (1997) 1.10
Helical structure of Bordetella pertussis fimbriae. J Bacteriol (1986) 1.10
Group B streptococcal opacity variants. J Bacteriol (1992) 1.05
Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotonic activities of Escherichia coli heat-labile enterotoxin. Infect Immun (1994) 1.05
Establishing a method of vector contamination identification in database sequences. Bioinformatics (1999) 1.04
Purification of serotype 2 fimbriae of Bordetella pertussis and their identification as a mouse protective antigen. Dev Biol Stand (1985) 1.02
Kinetic and antigenic characterization of altered protein synthesis by Campylobacter jejuni during cultivation with human epithelial cells. J Infect Dis (1993) 1.00
Proliferative response of immune mouse T-lymphocytes to the lymphocytosis-promoting factor of Bordetella pertussis. Infect Immun (1984) 0.95
Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1. Proc Natl Acad Sci U S A (1990) 0.93
Cloning and expression of the hup encoding a histone-like protein of Campylobacter jejuni. Gene (1994) 0.93
Mouse respiratory infection models for pertussis. Methods Enzymol (1994) 0.91
The role of cysteine 41 in the enzymatic activities of the pertussis toxin S1 subunit as investigated by site-directed mutagenesis. J Biol Chem (1990) 0.91
Biochemical and immunological properties of two forms of pertactin, the 69,000-molecular-weight outer membrane protein of Bordetella pertussis. Infect Immun (1993) 0.89
Effectors increase the affinity of ADP-ribosylation factor for GTP to increase binding. J Biol Chem (2000) 0.88
Antibodies to Bordetella pertussis in human colostrum and their protective activity against aerosol infection of mice. Infect Immun (1985) 0.87
The Genome Sequence DataBase (GSDB): improving data quality and data access. Nucleic Acids Res (1998) 0.87
Characterization of the filamentous hemagglutinin from Bordetella pertussis by gel electrophoresis. Mol Cell Biochem (1986) 0.87
Effects of mutations on enzyme activity and immunoreactivity of the S1 subunit of pertussis toxin. Infect Immun (1989) 0.86
Inhibition of class II major histocompatibility complex antigen processing by Escherichia coli heat-labile enterotoxin requires an enzymatically active A subunit. Infect Immun (1998) 0.86
Characterization of a recombinant fragment that contains a carbohydrate recognition domain of the filamentous hemagglutinin. Infect Immun (1997) 0.85
Frame-shift mutation in the lacZ gene of certain commercially available pUC18 plasmids. Nucleic Acids Res (1989) 0.85
Chinchilla model of experimental otitis media for study of nontypable Haemophilus influenzae vaccine efficacy. Methods Enzymol (1994) 0.85
Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant. J Immunol (2000) 0.85
Cloning, sequencing, and expression of a gene from Campylobacter jejuni encoding a protein (Omp18) with similarity to peptidoglycan-associated lipoproteins. Infect Immun (1996) 0.84
Evaluation of the mouse model for study of encephalopathy in pertussis vaccine recipients. Infect Immun (1989) 0.82
ARF binds the C-terminal region of the Escherichia coli heat-labile toxin (LTA1) and competes for the binding of LTA2. Biochemistry (2001) 0.82
Involvement of filamentous hemagglutinin in the adherence of Bordetella pertussis to human WiDr cell cultures. Dev Biol Stand (1985) 0.82
Pattern of drug usage in bronchiolitis. J Clin Pharm Ther (1994) 0.81
Genetic mapping and characterization of Pseudomonas aeruginosa mutants that hyperproduce exoproteins. J Bacteriol (1985) 0.78
Trytophanase from Aeromonas liquefaciens. Subunit structure and aggregation of the enzyme into enzymatically active polymeric species. J Biol Chem (1973) 0.76
Identification of subpopulations of human urinary plasminogen activators. Thromb Haemost (1984) 0.75
Antigenic relationships among thiol-activated cytolysins. Infect Immun (1977) 0.75
Modulation of secreted plasminogen activator activity of human renal carcinoma cells by dimethylsulfoxide, butyrate and retinoate. Cancer Lett (1987) 0.75
Characterization of plasminogen activator from two human renal carcinoma cell lines. J Cell Physiol (1986) 0.75
Formation of stable complexes between urokinase and a human urinary component. Thromb Haemost (1985) 0.75
Developments toward a recombinant pertussis vaccine. Adv Exp Med Biol (1989) 0.75
Recombinant microbial ADP-ribosylating toxins of Bordetella pertussis, Vibrio cholerae, and enterotoxigenic Escherichia coli: structure, function, and toxoid vaccine development. Bioprocess Technol (1994) 0.75
Species differences in the expression of caseinolytic proteinases and plasminogen activators by bone marrow cells. Comp Biochem Physiol B (1986) 0.75
The molecular engineering of pertussis toxoid. Dev Biol Stand (1991) 0.75
Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1. Dev Biol Stand (1991) 0.75
Female protein, amyloidosis, and hormonal carcinogenesis in Turkish hamster: differences from Syrian hamster. Am J Physiol (1997) 0.75
Increased plasma proteinase activity of mice bearing the BCL1 leukemia. Haemostasis (1985) 0.75